CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Summary

This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects. Other purposes of this research study will be to determine what side effects are seen with this combination of medicines. The Phase II portion of the study will test how many patients show shrinkage in their tumor with this combination of medicines and what changes occur inside the cancer cells and blood cells after treatment.

Timeline

Start

2016-09-12

Primary completion

2023-01-10

Completion

2023-01-10

Publications

• Sridhar SK, Abass KS, Gowthami B, Naveen NR. Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy. Invest New Drugs. 2025 Aug;43(4):1070-1085. doi: 10.1007/s10637-025-01577-w. Epub 2025 Aug 22.

Drugs

Indications